Inhibrx Biosciences (INBX) Competitors

Harrow (NASDAQ:HROW) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Do institutionals & insiders hold more shares of HROW or INBX?

72.8% of Harrow shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, HROW or INBX?

Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Does the media prefer HROW or INBX?

In the previous week, Harrow had 17 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 19 mentions for Harrow and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.93 beat Harrow's score of 0.35 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate HROW or INBX?

Harrow presently has a consensus target price of $63.83, suggesting a potential upside of 77.86%. Given Harrow's stronger consensus rating and higher possible upside, equities analysts plainly believe Harrow is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inhibrx Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has higher earnings and valuation, HROW or INBX?

Inhibrx Biosciences has lower revenue, but higher earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$199.61M	6.60	-$17.48M	-$0.56	-64.09
Inhibrx Biosciences	$200K	1,770.18	$1.69B	$116.75	0.21

Is HROW or INBX more profitable?

Inhibrx Biosciences has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-10.19%	-25.01%	-4.27%
Inhibrx Biosciences	N/A	-85.12%	-58.90%

Summary

Harrow and Inhibrx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.